WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Canadian police charge 2 former UN employees with conspiracy to sell military equipment in LibyaIs journalist Vicky Xu preparing to return to China? — Radio Free AsiaPrince Louis birthday portrait taken by Kate Middleton is released on day he turns 6Canucks goalie Thatcher Demko will miss Game 2 against PredatorsJunta attacks in Myanmar’s Bago region kill 8, displace 6,000 — Radio Free Asia'Challengers' review: Prepare to get hot and botheredActivists interrupt Chinese ambassador's Harvard speech — Radio Free AsiaTen of the world's best airports for food and drinks, according to expertsBaltimore port to open deeper channel, enabling some cargo ships to pass after bridge collapseStarbucks vs federal labor agency: U.S. Supreme Court is set to hear oral arguments
2.6633s , 6498.0703125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Circuit news portal